Frederique Madeleine Penault-Llorca
Inserm · 1,023 works · 67,333 citations · h-index 108
Top works
- KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
- KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
- 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
- Breast cancer
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
- Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
- Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
- Analysis of PTEN , BRAF , and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
- An International Ki67 Reproducibility Study
- ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
- Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
- Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial